中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
19期
2969-2971
,共3页
高血压%贝那普利%炎症细胞因子
高血壓%貝那普利%炎癥細胞因子
고혈압%패나보리%염증세포인자
Hypertension%Cytokines%Benazepril
目的 探讨贝那普利对原发性高血压患者血浆炎性细胞因子白细胞介素(IL)-4、IL-8、IL-10水平的影响.方法 选择轻中度原发性高血压患者72例,采用随机数字表将患者分为贝那普利组(37例)与对照组(35例).对照组患者予以菲洛地平缓释片5 ag,1次/d.贝那普利组予以贝那普利片10 mg,1次/d,两组疗程均为8周.观察两组患者治疗前后血压和心率的变化,并进行血浆IL-4、IL-8、IL-10水平的测定及不良反应的观察.结果 治疗8周后,两组患者的血压均较前明显下降(t =2.87、2.43、2.31、2.23,P<0.05或P<0.01),且贝那普利组下降的幅度较对照组更明显(t=2.21、2.13,均P<0.05);同时两组患者血浆IL-4和IL-8水平均较前明显下降、血浆IL-10水平均较前明显上升(t=2.99、2.87、3.21、2.13、2.19、2.23,均P<0.05或P<0.01),且贝那普利组下降或上升的幅度较对照组更明显(t=2.21、2.13、2.34,均P<0.05).结论 贝那普利治疗原发性高血压具有良好的降压作用,安全性较好,能明显降低患者血浆IL-4和IL-8水平,提高IL-10水平,具有抑制血管壁炎性反应的作用.
目的 探討貝那普利對原髮性高血壓患者血漿炎性細胞因子白細胞介素(IL)-4、IL-8、IL-10水平的影響.方法 選擇輕中度原髮性高血壓患者72例,採用隨機數字錶將患者分為貝那普利組(37例)與對照組(35例).對照組患者予以菲洛地平緩釋片5 ag,1次/d.貝那普利組予以貝那普利片10 mg,1次/d,兩組療程均為8週.觀察兩組患者治療前後血壓和心率的變化,併進行血漿IL-4、IL-8、IL-10水平的測定及不良反應的觀察.結果 治療8週後,兩組患者的血壓均較前明顯下降(t =2.87、2.43、2.31、2.23,P<0.05或P<0.01),且貝那普利組下降的幅度較對照組更明顯(t=2.21、2.13,均P<0.05);同時兩組患者血漿IL-4和IL-8水平均較前明顯下降、血漿IL-10水平均較前明顯上升(t=2.99、2.87、3.21、2.13、2.19、2.23,均P<0.05或P<0.01),且貝那普利組下降或上升的幅度較對照組更明顯(t=2.21、2.13、2.34,均P<0.05).結論 貝那普利治療原髮性高血壓具有良好的降壓作用,安全性較好,能明顯降低患者血漿IL-4和IL-8水平,提高IL-10水平,具有抑製血管壁炎性反應的作用.
목적 탐토패나보리대원발성고혈압환자혈장염성세포인자백세포개소(IL)-4、IL-8、IL-10수평적영향.방법 선택경중도원발성고혈압환자72례,채용수궤수자표장환자분위패나보리조(37례)여대조조(35례).대조조환자여이비락지평완석편5 ag,1차/d.패나보리조여이패나보리편10 mg,1차/d,량조료정균위8주.관찰량조환자치료전후혈압화심솔적변화,병진행혈장IL-4、IL-8、IL-10수평적측정급불량반응적관찰.결과 치료8주후,량조환자적혈압균교전명현하강(t =2.87、2.43、2.31、2.23,P<0.05혹P<0.01),차패나보리조하강적폭도교대조조경명현(t=2.21、2.13,균P<0.05);동시량조환자혈장IL-4화IL-8수평균교전명현하강、혈장IL-10수평균교전명현상승(t=2.99、2.87、3.21、2.13、2.19、2.23,균P<0.05혹P<0.01),차패나보리조하강혹상승적폭도교대조조경명현(t=2.21、2.13、2.34,균P<0.05).결론 패나보리치료원발성고혈압구유량호적강압작용,안전성교호,능명현강저환자혈장IL-4화IL-8수평,제고IL-10수평,구유억제혈관벽염성반응적작용.
Objective To investigate the effects of Benazepril on inflammatory cytokines in patients with primary hypertension and its efficacy analysis.Methods 72 patients with mild to moderate primary hypertension were randomly divided into benazepril group(37 cases)and control group(35 cases).The control group patients were given felodipine sustained release tablets Stag,1 times daily.Benazepril group were given benazepril tablets 10mg,1 times daily.Both groups were treated for 8 weeks.Changes in blood pressure and heart rate,plasma inflammatory cytokine levels and the adverse reactions were observed.Results After 8 weeks of treatment,the patients' blood pressures were significantly decreased (t =2.87,2.43,2.31,2.23,P < 0.05 or P < 0.01) than before in both groups.And the decrease in the benazepril group was more obvious than that in the control group (t =2.21,2.13,all P < 0.05),while the patients' heart rates in the two groups showed no significant change (P > 0.05) ; Patients' plasma IL-4 and IL-8 levels decreased significantly,plasma IL-10 levels increased significantly (t =2.99,2.87,3.21,2.13,2.19,2.23,all P<0.05 or P<0.01),and the magnitude of decrease or increase in the benazepril group were more obvious compared with the control group (t =2.21,2.13,2.34,all P < 0.05).Conclusion Benazepril in the treatment of primary hypertension has good antihypertensive effect and security which can significantly reduce the plasma levels of proinflammatory cytokines IL-4 and IL-8 levels,improve the anti-inflammatory cytokine IL-10 levels,and has the role of suppressing the inflammatory response of the vessel wall.